Literature DB >> 30616792

Radiation therapy quality assurance in head and neck radiotherapy - Moving forward.

Lachlan McDowell1, June Corry2.   

Abstract

Head and Neck Cancer (HNC) radiation oncologists (ROs) enjoy the immense pleasure of curing patients, working within a large multidisciplinary team to effectively deliver curative intent treatment whilst also aiming to minimise late treatment toxicity. Secondary analyses of large-scale HNC clinical trials have shown the critical impact of the quality of radiotherapy plans, where protocol non-compliant plans have yielded inferior survival rates approximating 20%. The peer review process in routine day-to-day HNC practice shows that even in major academic centers a significant proportion of RT plans may require changes to the radiotherapy planning volume. Optimising the therapeutic ratio in HNC has been dramatically facilitated by intensity modulated radiotherapy (IMRT), but that technology has also increased the complexity of HNC radiotherapy treatment and high-volume centers with experienced clinicians may be best placed to deliver this most accurately. International consensus guidelines to standardise or benchmark best practice with respect to the RT-QA process in HNC are needed. The aim of this paper is to highlight the importance of the RT-QA process in the HNC treatment process and to make some recommendations for its inclusion in both clinical trials and routine clinical practice. Crown
Copyright © 2018. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chemoradiotherapy; Head and neck cancer; Intensity-modulated radiotherapy; Peer review; Quality assurance; Radiotherapy

Mesh:

Year:  2018        PMID: 30616792     DOI: 10.1016/j.oraloncology.2018.11.014

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  4 in total

Review 1.  Quality of Life, Toxicity and Unmet Needs in Nasopharyngeal Cancer Survivors.

Authors:  Lachlan McDowell; June Corry; Jolie Ringash; Danny Rischin
Journal:  Front Oncol       Date:  2020-06-12       Impact factor: 6.244

2.  Report on planning comparison of VMAT, IMRT and helical tomotherapy for the ESCALOX-trial pre-study.

Authors:  Steffi U Pigorsch; Severin Kampfer; Markus Oechsner; Michael C Mayinger; Petra Mozes; Michal Devecka; Kerstin K Kessel; Stephanie E Combs; Jan J Wilkens
Journal:  Radiat Oncol       Date:  2020-11-02       Impact factor: 3.481

3.  Head and neck cancers: Monitoring quality and reporting outcomes.

Authors:  Madhavi Chilkuri; Venkat Vangaveti; Justin Smith
Journal:  J Med Imaging Radiat Oncol       Date:  2021-12-01       Impact factor: 1.667

Review 4.  Radiotherapy Quality Assurance for Head and Neck Squamous Cell Carcinoma.

Authors:  Dirk Van Gestel; Tatiana Dragan; Vincent Grégoire; Mererid Evans; Volker Budach
Journal:  Front Oncol       Date:  2020-03-12       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.